Immunohistochemical ERG positivity is associated with decreased PSMA expression and lower visibility in corresponding [

Glutamate carboxypeptidase II Immunohistochemistry Neoplasm staging Positron emission tomography Prostatic neoplasms Transcriptional Regulator ERG

Journal

European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988

Informations de publication

Date de publication:
31 Jul 2024
Historique:
received: 12 05 2024
accepted: 17 07 2024
medline: 31 7 2024
pubmed: 31 7 2024
entrez: 31 7 2024
Statut: aheadofprint

Résumé

TMPRSS2:ERG gene fusion negatively regulates PSMA expression in prostate adenocarcinoma (PCa) cell lines. Therefore, immunohistochemical (IHC) ERG expression, a surrogate for an underlying ERG rearrangement, and PSMA expression patterns in radical prostatectomy (RPE) specimens of primary PCa, including corresponding PSMA-PET scans were investigated. Two cohorts of RPE samples (total n=148): In cohort #1 (n=62 patients) with available RPE and preoperative [ Cohort #1: PCa with IHC-ERG expression (35.5%) showed significantly lower IHC-PSMA expression and lower SUV IHC-ERG expression is significantly associated with more heterogeneous and lower IHC-PSMA tissue expression in two independent RPE cohorts. There is a strong association of ERG positivity in RPE tissue with lower [

Identifiants

DOI: 10.1007/s00259-024-06856-x PMID: 39083067
pubmed: 39083067
doi: 10.1007/s00259-024-06856-x
pii: 10.1007/s00259-024-06856-x
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2024. The Author(s).

Références

Maurer T, Gschwend JE, Rauscher I, Souvatzoglou M, Haller B, Weirich G, et al. Diagnostic Efficacy of 68Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer. J Urol. 2016;195:1436–43.
doi: 10.1016/j.juro.2015.12.025 pubmed: 26682756
Yaxley JW, Raveenthiran S, Nouhaud F-X, Samaratunga H, Yaxley WJ, Coughlin G, et al. Risk of metastatic disease on
doi: 10.1111/bju.14828 pubmed: 31141284
Rüschoff JH, Ferraro DA, Muehlematter UJ, Laudicella R, Hermanns T, Rodewald A-K, et al. What’s behind 68Ga-PSMA-11 uptake in primary prostate cancer PET? Investigation of histopathological parameters and immunohistochemical PSMA expression patterns. Eur J Nucl Med Mol Imaging. 2021;48:4042–53.
doi: 10.1007/s00259-021-05501-1 pubmed: 34386839 pmcid: 8484204
Woythal N, Arsenic R, Kempkensteffen C, Miller K, Janssen J-C, Huang K, et al. Immunohistochemical Validation of PSMA Expression Measured by 68Ga-PSMA PET/CT in Primary Prostate Cancer. J Nucl Med. 2018;59:238–43.
doi: 10.2967/jnumed.117.195172 pubmed: 28775203
Laudicella R, Rüschoff JH, Ferraro DA, Brada MD, Hausmann D, Mebert I, et al. Infiltrative growth pattern of prostate cancer is associated with lower uptake on PSMA PET and reduced diffusion restriction on mpMRI. Eur J Nucl Med Mol Imaging. 2022;49:3917–28.
doi: 10.1007/s00259-022-05787-9 pubmed: 35435496 pmcid: 9399036
Sheehan B, Neeb A, Buroni L, Paschalis A, Riisnaes R, Gurel B, et al. Prostate-Specific Membrane Antigen Expression and Response to DNA Damaging Agents in Prostate Cancer. Clin Cancer Res. 2022;28:3104–15.
doi: 10.1158/1078-0432.CCR-21-4531 pubmed: 35552383 pmcid: 9365343
Paschalis A, Sheehan B, Riisnaes R, Rodrigues DN, Gurel B, Bertan C, et al. Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer. Eur Urol. 2019;76:469–78.
doi: 10.1016/j.eururo.2019.06.030 pubmed: 31345636 pmcid: 6853166
Kranzbühler B, Sousa R, Prause L, Burger IA, Rupp NJ, Sulser T, et al. Impact of short-term Dutasteride treatment on prostate-specific membrane antigen expression in a mouse xenograft model. Cancer Rep. 2021;4:e1418.
doi: 10.1002/cnr2.1418
Bakht MK, Yamada Y, Ku S-Y, Venkadakrishnan VB, Korsen JA, Kalidindi TM, et al. Landscape of prostate-specific membrane antigen heterogeneity and regulation in AR-positive and AR-negative metastatic prostate cancer. Nat Cancer. 2023;4:699–715.
doi: 10.1038/s43018-023-00539-6 pubmed: 37038004 pmcid: 10867901
Sayar E, Patel RA, Coleman IM, Roudier MP, Zhang A, Mustafi P, Low JY, Hanratty B, Ang LS, Bhatia V, Adil M, Bakbak H, Quigley DA, Schweizer MT, Hawley JE, Kollath L, True LD, Feng FY, Bander NH, Corey E, Lee JK, Morrissey C, Gulati R, Nelson PS, Haffner MC. Reversible epigenetic alterations mediate PSMA expression heterogeneity in advanced metastatic prostate cancer. JCI Insight. 2023;8(7):e162907. https://doi.org/10.1172/jci.insight.162907 .
Yin L, Rao P, Elson P, Wang J, Ittmann M, Heston WDW. Role of TMPRSS2-ERG Gene Fusion in Negative Regulation of PSMA Expression. PLoS One. 2011;6:e21319.
doi: 10.1371/journal.pone.0021319 pubmed: 21731703 pmcid: 3123299
Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun X-W, et al. Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer. Science. 2005;310:644–8.
doi: 10.1126/science.1117679 pubmed: 16254181
Esgueva R, Perner S, LaFargue CJ, Scheble V, Stephan C, Lein M, et al. Prevalence of TMPRSS2–ERG and SLC45A3–ERG gene fusions in a large prostatectomy cohort. Mod Pathol. 2010;23:539–46.
doi: 10.1038/modpathol.2009.193 pubmed: 20118910 pmcid: 2848699
Scheble VJ, Braun M, Beroukhim R, Mermel CH, Ruiz C, Wilbertz T, et al. ERG rearrangement is specific to prostate cancer and does not occur in any other common tumor. Mod Pathol. 2010;23:1061–7.
doi: 10.1038/modpathol.2010.87 pubmed: 20473283 pmcid: 3606550
Sung J-Y, Jeon HG, Jeong BC, Seo SI, Jeon SS, Lee HM, et al. Correlation of ERG immunohistochemistry with molecular detection of TMPRSS2-ERG gene fusion. J Clin Pathol. 2016;69:586–92.
doi: 10.1136/jclinpath-2015-203314 pubmed: 26670747
Perner S, Rupp NJ, Braun M, Rubin MA, Moch H, Dietel M, et al. Loss of SLC45A3 protein (prostein) expression in prostate cancer is associated with SLC45A3-ERG gene rearrangement and an unfavorable clinical course. Int J Cancer. 2013;132:807–12.
doi: 10.1002/ijc.27733 pubmed: 22821757
Park K, Tomlins SA, Mudaliar KM, Chiu Y-L, Esgueva R, Mehra R, et al. Antibody-Based Detection of ERG Rearrangement-Positive Prostate Cancer. Neoplasia. 2010;12:590–IN21.
doi: 10.1593/neo.10726 pubmed: 20651988 pmcid: 2907585
Umbehr M, Kessler TM, Sulser T, Kristiansen G, Probst N, Steurer J, et al. ProCOC: The prostate cancer outcomes cohort study. BMC Urol. 2008;8:9.
doi: 10.1186/1471-2490-8-9 pubmed: 18559088 pmcid: 2441625
Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA, et al. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System. Am J Surg Pathol. 2016;40:244.
doi: 10.1097/PAS.0000000000000530 pubmed: 26492179
Moch H, Humphrey P, Ulbright T, Reuter V. WHO classification of tumours of the urinary system and male genital organs. Lyon: IARC; 2016. https://publications.iarc.fr/Book-And-Report-Series/Who-Classification-Of-Tumours/WHO-Classification-Of-Tumours-Of-The-Urinary-System-And-Male-Genital-Organs-2016 . Accessed 10 May 2024.
Demirci E, Kabasakal L, Sahin OE, Akgün E, Gültekin MH, Doganca T, et al. Can SUVmax values of Ga-68-PSMA PET/CT scan predict the clinically significant prostate cancer? Nucl Med Commun. 2019;40:86.
doi: 10.1097/MNM.0000000000000942 pubmed: 30395048
Verdu M, Trias I, Roman R, Rodon N, Garcia-Pelaez B, Calvo M, et al. ERG expression and prostatic adenocarcinoma. Virchows Arch. 2013;462:639–44.
doi: 10.1007/s00428-013-1415-3 pubmed: 23703293
Hupe MC, Philippi C, Roth D, Kümpers C, Ribbat-Idel J, Becker F, et al. Expression of Prostate-Specific Membrane Antigen (PSMA) on Biopsies Is an Independent Risk Stratifier of Prostate Cancer Patients at Time of Initial Diagnosis. Front Oncol. 2018;8 https://doi.org/10.3389/fonc.2018.00623 .
Roberts MJ, Morton A, Papa N, Franklin A, Raveenthiran S, Yaxley WJ, et al. Primary tumour PSMA intensity is an independent prognostic biomarker for biochemical recurrence-free survival following radical prostatectomy. Eur J Nucl Med Mol Imaging. 2022;49:3289–94.
doi: 10.1007/s00259-022-05756-2 pubmed: 35298693 pmcid: 9250456
Acs B, Szarvas T, Szekely N, Nyirady P, Szasz AM. Current State of ERG as Biomarker in Prostatic Adenocarcinoma. Curr Cancer Drug Targets. 2015;15:643–51.
doi: 10.2174/156800961508151001100829 pubmed: 26452381
Ghosh A, Heston WDW. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem. 2004;91:528–39.
doi: 10.1002/jcb.10661 pubmed: 14755683
Mahmoud AM, Moustafa A, Day C, Ahmed ME, Zeina W, Marzouk UM, et al. Prostate Cancer Lung Metastasis: Clinical Insights and Therapeutic Strategies. Cancers (Basel). 2024;16:2080.
doi: 10.3390/cancers16112080 pubmed: 38893199
Udager AM, Shi Y, Tomlins SA, Alva A, Siddiqui J, Cao X, et al. Frequent discordance between ERG gene rearrangement and ERG protein expression in a rapid autopsy cohort of patients with lethal, metastatic, castration-resistant prostate cancer. Prostate. 2014;74:1199–208.
doi: 10.1002/pros.22836 pubmed: 25043157 pmcid: 4156519
Gsponer JR, Braun M, Scheble VJ, Zellweger T, Bachmann A, Perner S, et al. ERG rearrangement and protein expression in the progression to castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2014;17:126–31.
doi: 10.1038/pcan.2013.62 pubmed: 24469092 pmcid: 4097053
Cai C, Wang H, Xu Y, Chen S, Balk SP. Reactivation of androgen receptor-regulated TMPRSS2:ERG gene expression in castration-resistant prostate cancer. Cancer Res. 2009;69:6027–32.
doi: 10.1158/0008-5472.CAN-09-0395 pubmed: 19584279 pmcid: 2859723

Auteurs

Niels J Rupp (NJ)

Department of Pathology and Molecular Pathology, University Hospital Zurich, Schmelzbergstrasse 12, 8091, Zürich, Switzerland. niels.rupp@usz.ch.
University of Zurich, Zurich, Switzerland. niels.rupp@usz.ch.
ORCID: 0000-0002-7043-3456

Sandra N Freiberger (SN)

Department of Pathology and Molecular Pathology, University Hospital Zurich, Schmelzbergstrasse 12, 8091, Zürich, Switzerland.
University of Zurich, Zurich, Switzerland.

Daniela A Ferraro (DA)

Department of Nuclear Medicine, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Department of Radiology and Oncology, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, Brazil.

Riccardo Laudicella (R)

Department of Nuclear Medicine, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Department of Biomedical and Dental Sciences and Morpho-Functional Imaging, Nuclear Medicine Unit, University of Messina, Messina, Italy.

Jakob Heimer (J)

Seminar for Statistics, Federal Institute of Technology (ETH) Zurich, Zurich, Switzerland.

Urs J Muehlematter (UJ)

Department of Nuclear Medicine, University Hospital Zurich, University of Zurich, Zurich, Switzerland.

Cédric Poyet (C)

Department of Urology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.

Holger Moch (H)

Department of Pathology and Molecular Pathology, University Hospital Zurich, Schmelzbergstrasse 12, 8091, Zürich, Switzerland.
University of Zurich, Zurich, Switzerland.

Daniel Eberli (D)

University of Zurich, Zurich, Switzerland.
Department of Urology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.

Jan H Rüschoff (JH)

Department of Pathology and Molecular Pathology, University Hospital Zurich, Schmelzbergstrasse 12, 8091, Zürich, Switzerland.

Irene A Burger (IA)

Department of Nuclear Medicine, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Department of Nuclear Medicine, Cantonal Hospital Baden, affiliated Hospital for Research and Teaching of the Faculty of Medicine of the University of Zurich, Baden, Switzerland.

Classifications MeSH